Epione Pharma

Epione Pharma is a clinical-stage biotechnology company headquartered in Glasgow, Scotland, dedicated to developing next-generation therapies for chronic pain management. The company's primary focus is on peripheral neuropathic pain, a condition with significant unmet medical needs and a reliance on systemic treatments that often carry heavy side-effect profiles. Epione's lead program, EP-101, is a novel topical formulation of a sodium channel blocker designed to provide effective localized analgesia while minimizing systemic exposure. By leveraging advanced drug delivery technologies, the company aims to provide patients with safer and more effective alternatives to traditional oral pain medications like opioids. Epione Pharma works closely with clinical experts and regional innovation hubs to advance its pipeline through clinical proof-of-concept.